Alejandrina Rodriguez-Hernandez

Publications (2)2.75 Total impact

• Article: Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation.

  Alejandro D Soriano-Hernández, Hector R Galvan-Salazar, Daniel A Montes-Galindo, Alejandrina Rodriguez-Hernandez, Rafael Martinez-Martinez, Jose Guzman-Esquivel, Laura L Valdez-Velazquez, Luz M Baltazar-Rodriguez, Francisco Espinoza-Gómez, Augusto Rojas-Martinez, Rocio Ortiz-Lopez, Rafael Gonzalez-Alvarez, Ivan Delgado-Enciso
  [show abstract] [hide abstract]
  ABSTRACT: Prostate cancer is a worldwide public health problem and its treatment continues to be a therapeutic challenge especially in patients with metastatic androgen-independent cancer. Inflammation is a process that has been involved in the origin of this cancer and its inhibition has been postulated as a prophylactic and therapeutic strategy. The present study evaluated two non-steroidal anti-inflammatory drugs (meclofenamic acid and mefenamic acid) that have been studied very little in regard to cancer treatment. In vitro, the cytotoxic effects of meclofenamic acid and mefenamic acid were determined in human prostate cancer cell lines (LNCaP: androgen-dependent; and PC3: androgen-independent). In vivo trials were divided into two phases; meclofenamic acid toxicity was initially determined at different doses (0, 5, 10 and 20 mg/kg/day/25 days) in BALB/c mice, after which a trial using non-toxic doses was carried out to evaluate the antitumor efficacy of the drug in a PC3/nude-mouse model of human androgen-independent prostate cancer. In vitro trials showed that only meclofenamic acid is highly cytotoxic in neoplastic prostate cells. The 5 and 10 mg/kg/day/25 day doses did not cause relevant toxicity in the BALB/c mouse trial, and so both doses were used in the nude-mouse model of cancer trial. This latter trial showed that meclofenamic acid significantly reduces tumor growth, prolongs survival, and is even capable of generating total tumor regression in up to 25% of mice treated at high dose. Meclofenamic acid was shown to be a potential antineoplastic agent for both androgen-dependent and androgen-independent prostate cancer.
  International Urology and Nephrology 06/2011; 44(2):471-7. · 1.47 Impact Factor
• Source

  Available from: Iram Rodriguez

  Article: Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population.

  Iván Delgado-Enciso, Friedman R Cepeda-Lopez, Elisa A Monrroy-Guizar, Jose R Bautista-Lam, Maricela Andrade-Soto, Gregorio Jonguitud-Olguin, Alejandrina Rodriguez-Hernandez, Aristoteles Anaya-Ventura, Luz M Baltazar-Rodriguez, Martha Orozco-Ruiz, Alejandro D Soriano-Hernandez, Iram P Rodriguez-Sanchez, Angel Lugo-Trampe, Francisco Espinoza-Gomez, Martha L Michel-Peregrina
  [show abstract] [hide abstract]
  ABSTRACT: Matrix metalloproteinase-2 (MMP-2) is an enzyme with proteolytic activity on matrix proteins, particularly basement membrane constituents. A single nucleotide polymorphism C>T transition at -1306 displayed a strong association with several cancers. Our study investigated whether or not the MMP-2 -1306C>T polymorphism contributed to the development of breast cancer (BC) in a Mexican population. 90 patients with BC and 96 control subjects were analyzed to detect MMP-2 -1306C>T polymorphism. The frequency of MMP-2 CC genotype was significantly higher in BC patients when compared with the control group (OR 2.15; 95% CI 1.1-4.1). MMP-2 CC genotype frequency was more pronounced in younger subjects (< or =50 years) at diagnosis (OR 2.66; 95% CI 1.04-6.96). The data suggest that MMP-2 -1306C>T polymorphism strongly contributes to the development of BC in the population studied, especially among women 50 years old and younger.
  Gynecologic and Obstetric Investigation 01/2008; 65(1):68-72. · 1.28 Impact Factor